Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04809363 · ClinicalTrials.gov registry record · Phase 4
A Study of CDPATH™ to Help Manage and Treat Crohn's Disease
A Phase 4 study of Crohn's Disease, sponsored by Takeda.
- Active
- Registry status
- Phase 4
- Development phase
- 200
- Enrollment target
- 20
- Study locations
NCT04809363: Active Phase 4 study of Crohn's Disease, sponsored by Takeda.
NCT04809363 is a Phase 4 study of Crohn's Disease that is active but no longer recruiting, run by Takeda. The registered enrollment target is 200 participants, below the 2,393-participant average among 105 other Crohn's Disease trials with a reported enrollment target (92% lower). The trial reports 20 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04809363, a Phase 4 study of Crohn's Disease, is active but no longer recruiting, sponsored by Takeda.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 4
- Development phase
- 200 participants
- Enrollment target
- 20
- Study locations
Study Summary
CDPATH™ is a tool to help predict the potential for developing Crohn's disease related complications in certain adult participants within 3 years. The main aim of the study is to explore the use of CDPATH™ to describe a participant's risk profile and to have discussions with their doctor about the potential path of their Crohn's disease. The number of visits will be decided by the study clinic according to their standard practice.
Primary Outcome
The risk profile of an individual participant with CD is the output of the CDPATH™ tool. Categories for CD includes low, medium, high risk of developing a CD complication within 3 years.
Conditions Studied
Interventions
- OTHER Blood Draw
- OTHER CDPATH™
Study Locations (20)
California
- VA Loma Linda Healthcare System - Loma Linda
- United Medical Doctors - Murrieta
- University of Southern California Medical Center - Newport Beach
- Clinnova Research Solutions - Orange
- University of California at Irvine Medical Center - Orange
Illinois
- GI Alliance - Arlington Heights
- GI Alliance - Gurnee
- Comprehensive Gastrointestinal Health - Northbrook
- Rockford Gastroenterology Associates, Ltd. - Rockford
Florida
- West Central Gastroenterology d/b/a Gastro Florida - Clearwater
- Gastroenterology Associates of Pensacola, PA - Pensacola
Iowa
- Iowa Digestive Disease Center - Clive
- University of Iowa Hospitals & Clinics - Iowa City
Arizona
- Arizona Arthritis & Rheumatology Research, PLLC - Phoenix
Colorado
- Kaiser Permanate of Colorado - Aurora
Connecticut
- Medical Research Center of Connecticut, LLC - Hamden
Idaho
- Grand Teton Research Group, PLL - Idaho Falls
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2021-06-25 |
| Est. Completion | 2026-09-12 |
| Phase | Phase 4 |
What the registry record for NCT04809363 still lists
NCT04809363 is an interventional study that assigns participants to a tested intervention. The registered 200 participants enrollment target is mid-sized for trials with a published cap, below the 2,393-participant average among 105 other Crohn's Disease trials with a reported enrollment target (92% lower).
The record links to 1 condition, with Crohn's Disease appearing as the primary indexed condition, and to 2 interventions - of which Blood Draw is the first listed.
NCT04809363 names 20 study sites across 11 states, led by California, Illinois, Florida.
Frequently Asked Questions
What is clinical trial NCT04809363 about?
NCT04809363 is a clinical study titled "A Study of CDPATH™ to Help Manage and Treat Crohn's Disease". CDPATH™ is a tool to help predict the potential for developing Crohn's disease related complications in certain adult participants within 3 years. The main aim of the study is to explore the use of CDPATH™ to describe a participant's risk profile and to have discussions with their doctor about the p...
What is the current status of trial NCT04809363?
This trial is currently active not recruiting. It is a Phase 4 study. The enrollment target is 200 participants. The study started on 2021-06-25. Estimated completion is 2026-09-12.
What conditions does trial NCT04809363 study?
This clinical trial studies the following conditions: Crohn's Disease.
What interventions are being tested in trial NCT04809363?
The interventions under investigation include: Blood Draw (OTHER), CDPATH™ (OTHER).
Who is sponsoring clinical trial NCT04809363?
This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04809363 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Crohn's Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04809363's enrollment target sits among peer trials
200 52nd of 105 higher than 54 of 105 other Crohn's Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Crohn's Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease
RECRUITING · Phase 4
-
A Study of Vedolizumab in Adults With Ulcerative Colitis or Crohn's Disease in the Community Setting
RECRUITING · Phase 4
-
Postmarketing Vedolizumab Milk-Only Lactation Study in Lactating Women With Active Ulcerative Colitis or Crohn's Disease
COMPLETED · Phase 4
-
Centocor Microarray Study of Patients
COMPLETED · Phase 4
-
A Pilot Study to Assess the Safety, Tolerability, and Efficacy of Virtual Reality for the Treatment of Abdominal Pain in Quiescent Crohn's Disease
RECRUITING · NA
-
A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00107289 · 200 participants · Phase 2
Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma
- NCT00109174 · 200 participants · NA
MRS Measurement of Glutamate and GABA Metabolism in Brain
- NCT00177268 · 200 participants
Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research
- NCT00493688 · 200 participants
A Study to Determine Whether Perioperative Energy Dynamics Correlates With Postoperative Outcomes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI